Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
October 04 2021 - 5:32PM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced a presentation at the Chardan Virtual
5th Annual Genetic Medicines Conference on Tuesday, October 5,
2021.
Date: Tuesday, October 5, 2021 Time: 11:00 – 11:25 AM Eastern
Time Location: Virtual Webcast
The presentation will be available for live streaming via
https://wsw.com/webcast/chard9/xcur/1885590
Replays of the webcast will be available on Exicure’s website
for 30 days following the webcast.
About Exicure, Inc. Exicure, Inc. is a clinical-stage
biotechnology company developing therapeutics for neurology,
immuno-oncology, inflammatory diseases and other genetic disorders
based on its proprietary Spherical Nucleic Acid, or SNA technology.
Exicure believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA. www.exicuretx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211004005987/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024